Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/126130
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Effects of intraduodenal administration of the artificial sweetener sucralose on blood pressure and superior mesenteric artery blood flow in healthy older subjects
Author: Pham, H.
Stevens, J.
Rigda, R.
Phillips, L.
Wu, T.
Hausken, T.
Soenen, S.
Visvanathan, R.
Rayner, C.
Horowitz, M.
Jones, K.
Citation: American Journal of Clinical Nutrition, 2018; 108(1):156-162
Publisher: Oxford University Press (OUP)
Issue Date: 2018
ISSN: 0002-9165
1938-3207
Statement of
Responsibility: 
Hung T Pham, Julie E Stevens, Rachael S Rigda, Liza K Phillips, Tongzhi Wu, Trygve Hausken, Stijn Soenen, Renuka Visvanathan, Christopher K Rayner, Michael Horowitz, and Karen L Jones
Abstract: Background:Postprandial hypotension (PPH) occurs frequently, particularly in older people and those with type 2 diabetes, and is associated with increased morbidity and mortality. The magnitude of the decrease in blood pressure (BP) induced by carbohydrate, fat, and protein appears to be comparable and results from the interaction of macronutrients with the small intestine, including an observed stimulation of mesenteric blood flow. It is not known whether artificial sweeteners, such as sucralose, which are widely used, affect BP. Objective:The aim of this study was to evaluate the effects of intraduodenal sucralose on BP and superior mesenteric artery (SMA) blood flow, compared with intraduodenal glucose and saline (control), in healthy older subjects. Design:Twelve healthy subjects (6 men, 6 women; aged 66-79 y) were studied on 3 separate occasions in a randomized, double-blind, crossover design. After an overnight fast, subjects had concurrent measurements of BP and heart rate (HR; automated device), SMA blood flow (Doppler ultrasound), and blood glucose (glucometer) during intraduodenal infusion of 1) glucose (25% wt:vol, ∼1400 mOsmol/L), 2) sucralose (4 mmol/L, ∼300 mOsmol/L), or 3) saline (0.9% wt:vol, ∼300 mOsmol/L) at a rate of 3 mL/min for 60 min followed by intraduodenal saline for a further 60 min. Results:There was a decrease in mean arterial BP (P < 0.001) during intraduodenal glucose [baseline (mean ± SEM): 91.7 ± 2.6 mm Hg compared with t = 60 min: 85.9 ± 2.8 mm Hg] but not during intraduodenal saline or intraduodenal sucralose. The HR (P < 0.0001) and SMA blood flow (P < 0.0001) also increased during intraduodenal glucose but not during intraduodenal saline or intraduodenal sucralose. As expected, blood glucose concentrations increased in response to glucose (P < 0.0001) but not saline or sucralose. Conclusions:In healthy older subjects, intraduodenal administration of the artificial sweetener sucralose was not associated with changes in BP or SMA blood flow. Further studies are therefore warranted to determine the potential role for artificial sweeteners as a therapy for PPH. This trial was registered at http://www.ANZCTR.org.au as ACTRN12617001249347.
Keywords: postprandial hypotension; sucralose; blood pressure; superior mesenteric artery blood flow; artificial sweetener
Description: First published online June 6, 2018
Rights: © 2018 American Society for Nutrition. All rights reserved.
DOI: 10.1093/ajcn/nqy060
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.